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Abstract: The pathophysiological roles of mast cells are still not fully understood, over 140 years
since their description by Paul Ehrlich in 1878. Initial studies have attempted to identify distinct
“subpopulations” of mast cells based on a relatively small number of biochemical characteristics.
More recently, “subtypes” of mast cells have been described based on the analysis of transcriptomes of
anatomically distinct mouse mast cell populations. Although mast cells can potently alter homeostasis,
in certain circumstances, these cells can also contribute to the restoration of homeostasis. Both solid
and hematologic tumors are associated with the accumulation of peritumoral and/or intratumoral
mast cells, suggesting that these cells can help to promote and/or limit tumorigenesis. We suggest
that at least two major subsets of mast cells, MC1 (meaning anti-tumorigenic) and MC2 (meaning
pro-tumorigenic), and/or different mast cell mediators derived from otherwise similar cells, could
play distinct or even opposite roles in tumorigenesis. Mast cells are also strategically located in the
human myocardium, in atherosclerotic plaques, in close proximity to nerves and in the aortic valve.
Recent studies have revealed evidence that cardiac mast cells can participate both in physiological
and pathological processes in the heart. It seems likely that different subsets of mast cells, like those
of cardiac macrophages, can exert distinct, even opposite, effects in different pathophysiological
processes in the heart. In this chapter, we have commented on possible future needs of the ongoing
efforts to identify the diverse functions of mast cells in health and disease.
Keywords: allergy; atherosclerosis; cancer; cancer-related inflammation; mast cell; myocardial
infarction; predictive biomarker; tumor-associated mast cells
1. Introduction
The functions of mast cells are still not fully understood, now over 140 years since their description
by Paul Ehrlich in 1878 [1]. However, efforts to discern their development have revealed two pathways
resulting in mast cells, at least in mice: those which govern the generation of progenitors in the yolk sac
and those which modulate the differentiation of precursors in the bone marrow [2–5]. Similarly, it is now
clear that some mast cell populations can undergo relatively rapid changes in population size, notably
including so-called “mucosal mast cells” in the mouse gastrointestinal tract [6] or both “mucosal” and
“connective tissue” mast cells in animals provided with recombinant stem cell factor [7,8]. By contrast,
other mast cells can persist for years, at least in laboratory rodents [9].
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Unsurprisingly, a number of studies have attempted to identify distinct “subpopulations” of mast
cells. These range from the very old [10,11] to more modern efforts that have documented multiple
morphological “types” of mast cells (work extended by Enerback [12]) to those that are based on
a relatively small number of biochemical characteristics, such as the mast cell’s content of tryptase
vs. chymase [13]. More recently, additional “subtypes” of mast cells have been described, based on
the comprehensive analysis of the transcriptome of individual anatomically distinct mouse mast cell
populations [14]. Indeed, some time ago, the idea was discussed that: (1) given the extraordinarily
long life span of some mast cells, and, (2) in light of their ability to respond with phenotypic alterations
in response to so many internal and external signals, it seems possible that mast cells encountered
in vivo are ”tunable”, at least for some products or functions [15].
What then are the “key features” which must be taken into account in assigning mast cells to
phenotypically different “subtypes”? And how stable are these phenotypes, particularly for mast
cells in vivo? These are just some of the questions to address when considering the complexities of
discerning distinct functions of mast cells in humans, especially in non-IgE-mediated processes.
In this chapter, we will review particularly the broad range of possible roles of mast cells in human
diseases, especially in malignancies or cardiovascular disorders.
2. The Mast Cell in Homeostasis
Although mast cells are regarded as cells that are potently able to disturb homeostasis, for example
in the case of food-induced anaphylaxis, this is not their only function. Indeed, in certain circumstances,
mast cells can contribute to the restoration of homeostasis.
Grimbaldeston et al. [16] showed, using mast cell-deficient WBB6F1-KitW/W-v mice and
C57BL/6-KitW-sh/W-sh mice, that mast cells can dampen the extent of either severe contact hypersensitivity
(CHS) reactions induced by urushiol (a toxin produced by poison ivy or poison sumac) or severe
responses to ultraviolet B irradiation. Furthermore, evidence was provided that some of this mast
cell-dependent suppression of the extent of inflammation and tissue damage was due to mast cell
production of IL-10. Recently, Reber et al. [17] showed that this “mast cell-dependent” suppression of
severe CHS also could be detected when the CHS was elicited by dintrofluorobenzene (DNFB) and
when the experiments were done using more “modern” mast cell-deficient mice, namely, Cpa3-Cre;
Mcl-1fl/fl mice or Mcpt5-Cre+ mice. Furthermore, in vivo imaging studies showed that mast cell IL-10
expression was markedly augmented in the mast cells participating in severe, as opposed to mild,
CHS reactions to DNFB [17].
The finding that IL-10 production by mast cells can help to dampen inflammation was also
reported by Soman Abraham’s group [18]. That study investigated the participation of urinary tract
mast cells in bacterial infection of the bladder [18]. The set of signals that inform mast cells that they
should upregulate IL-10 production, in either setting, is currently unknown. However, these findings
suggest that one function of the mast cell may be to maintain homeostasis of tissues by helping to
dampen strong reactions, in part by expressing higher amounts of certain products (e.g., IL-10).
3. Protective Roles of Mast Cells
There are two settings in which some mast cell functions appear to be protective. In both cases,
the data come from studies of different varieties of mast cell-deficient mice. While early work in these
models employed older types of mast cell-deficient mice (i.e., mast cell-deficient WBB6F1-KitW/W-v mice
and C57BL/6-KitW-sh/W-sh mice), more recent work with more modern varieties of mast cell-deficient
mice has produced similar findings.
First, mast cells have been associated with primary infections to certain parasites, including
Strongyloides species. Two recent studies, which used different types of c-Kit independent mast
cell-deficient mice, have confirmed a role for mast cells in reducing the length of primary infections
with Strongyloides ratti [19] or S. brasiliensis [20]. Notably, little or no role of mast cells was detected in
either study during secondary infections with the parasite. These recent studies therefore confirm and
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extend prior work, employing mast cell-deficient WBB6F1-KitW/W-v mice, which also suggested a role
for mast cells (and IL-3) in limiting the length of infection with S. brasiliensis [21].
Second, mast cells have been shown to be important for the full expression of both primary and
secondary responses to the venoms of the honeybee and the Russell’s viper [22–24]. In the case of
primary responses, different mast cell proteases appear to play important roles in mediating resistance
to some venoms. For example, carboxypeptidase A appears to play an important role in mediating
primary resistance to either the whole venom of the snake, Atractaspis engaddensis [22] or to a major toxin
in the venom, sarafotoxin [22,25]. By contrast, mouse mast cell protease 4 (thought to be equivalent to
human chymase) appears to be important in primary immune responses to the venoms of the Gila
monster lizard (Heloderma suspectum) and to two species of highly toxic scorpions [26].
Notably, the World Health Organization recently designated envenomation by snake bite to its
list of category A neglected tropical diseases [27]. Anderson et al. [28] tested the ability of recombinant
human tryptase β to detoxify six different venoms from phylogenetically distinct snakes, using a
zebrafish embryo model system. Human mast cell tryptase β, but not other tested proteases (human
mast cell chymase or CPA), detoxified each of these six venoms by mass spectrometry, limiting their
ability to kill the zebrafish embryos. This result is especially interesting because, unlike other serine
proteases, tryptase β is active as a tetramer, thereby preventing it from degrading proteins too large to
be accommodated within its central pore. Anderson et al. [28] carefully noted that only the zebrafish
embryo toxicity model was used in their study, and that different toxins (possibly with increased
resistance to tryptase digestion) might participate in toxicity in humans; that injection of relatively
large amounts of recombinant tryptase βmight result in adverse effects; and that satisfactory methods
had to be developed to store and apply the enzyme in the field. Nevertheless, the work is consistent
with the idea that recombinant human tryptase β could potentially be used as a first aid treatment for
those bitten by a variety of poisonous snakes.
4. Mast Cells in Cancer
Rudolf Virchow first made a connection between inflammation and cancer in the 19th century,
based on the observation that tumors often arose at sites of chronic inflammation and that immune cells
were present in tumors [29]. The presence of mast cells in human tumors was first reported by Paul
Ehrlich [1] and was extended by Eugene Westphal [30]. Tumorigenesis is a process characterized by the
accumulation of genetic and epigenetic alterations [31], and the tissue microenvironment plays a central
role in maintaining tissue homeostasis or promoting tumors. Thus, the normal microenvironment
is considered a barrier to tumorigenesis [32], whereas a collection of “inappropriate” signals (e.g.,
chemokines, cytokines, reactive oxygen species, reactive nitrogen species, lipid mediators, etc.) can
initiate and promote tumors. Indeed, low grade inflammation or smoldering inflammation is a
hallmark of cancer [33] and immune cells (macrophages, lymphocytes, neutrophils, mast cells, NK and
NKT cells, eosinophils, etc.) are components of the inflammatory microenvironment that can play a
role in the development of experimental and human tumors [33–36].
Both solid and hematopoietic tumors are associated with the accumulation of peritumoral
and/or intratumoral mast cells [37–40], suggesting that they play a role in promoting and/or limiting
tumorigenesis. Indeed, there is evidence consistent with both of these functions in experimental
and clinical studies [37,41]. For example, peritumoral and/or intratumoral mast cell density is
increased in different types of human cancer [42]. Moreover, a variety of tumor products can serve
to attract mast cells into the tumor microenvironment (TME) (Figure 1), including stem cell factor
(SCF) [43,44], vascular endothelial growth factors (VEGFs) [45,46], angiopoietin 1 (ANGPT1) [47],
several chemokines (CXCL8, CXCL2, CXCL1, and CXCL10) [46,48,49], prostaglandin E2 (PGE2) [50,51],
TSLP [52], and osteopontin [53].
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Figure 1. Mast cells can be recruited into tumor microenvironments (TMEs) by several chemotactic 
molecules (e.g., SCF, VEGFs, PGE2, CXCL8, CCL2, CXCL1, CXCL10, osteopontin) produced by tumor 
or immune cells [49]. However, mast cells in the TME can exert anti-tumorigenic and/or pro-
tumorigenic roles. Similarly to neutrophils (N1 and N2) and macrophages (M1 and M2), it is possible 
that the complex biochemical milieu of the TME (and of tumor cells themselves) can polarize mast 
cells toward anti-tumorigenic MC1 or pro-tumorigenic MC2 mast cell types. Reactive oxygen species 
(ROS) are chemically reactive free radicals that potentially function as a double-edged sword [54]. 
Rodent and human mast cells can produce functionally active ROS [55] and excessive ROS may 
induce cytotoxic effects that can contribute to tumor regression. Mast cells also can exert direct tumor 
cytotoxic effects via TNF-α [56–59] and/or granzyme B [60,61]. IL-9 produced by mast cells can inhibit 
tumor cell engraftement [62]. Histamine promotes dendritic cell (DC) maturation and inhibits tumor 
growth [63,64]. Tryptase can be taken up into the nucleus of human melanoma cells causing 
truncation of histones and inhibition of cell proliferation [65]. Human mast cells also can release 
lymphangiogenic factors (VEGF-C and VEGF-D) [45,66], and increasing evidence indicates that 
lymphangiogenesis can play an active role in the resolution of inflammation [67,68]. However, the 
presence of large amounts of ROS can outstrip the capacity of cellular DNA repair systems, triggering 
genomic instability and transcription errors that may foster tumor initiation [69]. Mast cells also 
represent a potentially major source of several angiogenic molecules (VEGF-A, VEGF-B, FGF-2, 
tryptase) [45,70–74]. In addition, MMP-9 can induce degradation of the extracellular matrix, leading 
to cancer cell invasion and metastasis [75]. TGF-β, CXCL8 and TNF-α can induce epithelial-to-
mesenchymal transition [48,76]. Proinflammatory cytokines such as IL-1β [49,77–81] and IL-6 [82,83] 
can contribute to chronic inflammation in tumor microenvironment. IL-13 favors M2 polarization of 
tumor-associated macrophages [77]. Adenosine can be released by activated mast cells and 
Figure 1. Mast cells can be recruited into tumor microenvironments (TMEs) by several chemotactic
molecules (e.g., SCF, VEGFs, PGE2, CXCL8, CCL2, CXCL1, CXCL10, osteopontin) produced by tumor or
immune cells [49]. However, mast cells in the TME can exert anti-tumorigenic and/or pro-tumorigenic
roles. Similarly to neutrophils (N1 and N2) a macrophages (M1 and M2), it is possible that the
complex bio hemical mili u of the TME (and of tumor cells themselv s) can pol rize mast cells toward
anti-tumorigenic MC1 pro-tumorigenic MC2 mast cell types. Reactiv oxygen species (ROS) are
chemically reactive free radicals that potentially function as a double-edged sword [54]. Rodent and
human mast cells can produce functionally active ROS [55] and excessive ROS may induce cytotoxic
effects that can contribute to tumor regression. Mast cells also can exert direct tumor cytotoxic effects
via TNF-α [56–59] and/or granzyme B [60,61]. IL-9 produced by mast cells can inhibit tumor cell
engraftement [62]. Histamine promotes dendritic cell (DC) maturation and inhibits tumor growth [63,64].
Tryptase can be taken up into the nucleus of human melanoma cells causing truncation of histones
and inhibition of cell pr liferation [65]. Human mast cells also an release lymphangiogenic factors
(VEGF-C and VEGF-D) [45,66], and increasing evidence indicates that lymphangiogen sis can play an
active role in the resolutio of inflammation [67,68]. However, the presence of large amounts of ROS can
outstrip the capacity of cellular DNA repair systems, triggering genomic instability and transcription
errors that may foster tumor initiation [69]. Mast cells also represent a potentially major source of
several angiogenic molecules (VEGF-A, VEGF-B, FGF-2, tryptase) [45,70–74]. In addition, MMP-9
can induce degradation of the extracellular matrix, leading to cancer cell invasion and metastasis [75].
TGF-β, CXCL8 and TNF-α can induce epithelial-to-mesenchymal transition [48,76]. Proinflammatory
cytokines such as IL-1β [49,77–81] and IL-6 [82,83] can contribute to chronic inflammation in tumor
microenvironment. IL-13 favors M2 polarization of tumor-associated macrophages [77]. Adenosine
can be released by activated mast cells and potentiates the release of angiogenic and lymphangiogenic
factors from human mast cells [45]. VEGF-C and VEGF-D are the major lymphangiogenic factors
produced by human mast cells and can contribute to the formation of metastasis [84,85].
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In several studies, mast cells appeared to play a pro-tumorigenic role in human and experimental
tumors [37,86]. Evidence for an anti-tumorigenic role for mast cells was also found in certain
tumors [62,87,88], whereas a limited number of studies indicate a non-contributing role of mast
cells in certain tumors [37,41,89,90]. As illustrated in Figure 1, these apparently conflicting results are
compatible with the hypothesis that different subsets of mast cells and/or different mast cell-derived
mediators can play distinct or even opposite roles in tumorigenesis. Future studies should address the
possible roles of plasticity/ hypothetical subtypes of mast cells in different cancers, or at different stages
of tumorigenesis.
4.1. Sublocalization of Mast Cells in Different Stages of Tumor Development
Increasing evidence suggests that the roles of immune cells in tumors vary according to their
microlocalization. For instance, sublocalization of lymphocytes can contribute to the prognosis and
even to the predictive stratification of patients with breast cancer [91]. Most initial studies evaluating
mast cell density in cancer did not examine differences between the sublocalization (the periphery vs.
the center) of tumors. Future analyses assessing the spatial distribution of mast cells should evaluate
not only their density, but also their state of activation in distinct tumor compartments such as the
margin, the tumor core, and macroscopically normal adjacent tissue. It has already been demonstrated
that the density of mast cells, as well as several other immune cells, differs in the center of the colorectal
carcinoma vs. at the invasive margin [92]. This study also reported differences in mast cell density
in different tumor stages. These findings suggest that the microlocalization of mast cells should be
investigated in different stages of clinical and experimental tumors.
Indeed, recent results have highlighted marked differences in the phenotypic, genetic and
functional characteristics of a variety of tumor-associated immune cells at early vs. late stages of human
tumors [93–96]. There is already some evidence that the role of mast cells may vary according to the
stage of tumorigenesis. This has been suggested in studies in melanoma [87], prostate cancer [97,98],
non-small cell lung cancer (NSCLC) [99], and colon cancer [100]. However, more studies are needed to
characterize the possible metabolic alterations of mast cells residing in different areas, or in different
stages, of tumors in order to identify potential therapeutic targets.
4.2. Heterogeneity of Mast Cells in Cancer
The potentially dual role (i.e., pro-tumorigenic and anti-tumorigenic) of mast cells in cancer
raises the issue of mast cell heterogeneity in cancer. Recently, the marked heterogeneity of several
immune cells has been demonstrated by using single-cell sequencing [101,102]. For example, several
recent studies demonstrate that the model distinguishing classically polarized anti-tumor M1 and
alternatively polarized pro-tumor M2 subtypes [77] incompletely accounts for the in vivo diversity
of macrophages [94,102]. Similarly, the predictive potential of the transcriptionally and functionally
heterogeneity of intratumoral CD8+ T cells has been demonstrated in NSLC [103]. Moreover, two subsets
of conventional dendritic cells (DC1 and DC2) [104], neutrophils (N1 and N2) [105,106] and γδ T cells
in cancer have been demonstrated [107]. The application of single-cell RNA sequencing (scRNA-seq)
platforms will allow high resolution characterization of different subsets of mast cells that accompany
tumor initiation and growth. Indeed, one might speculate that at least two major subsets of mast
cells, MC1 (meaning anti-tumorigenic) and MC2 (meaning pro-tumorigenic), could play a role in
tumorigenesis (Figure 1).
4.3. PD-L1 Expression on Mast Cells
The clinical development of checkpoint inhibitor-based immunotherapy has ushered in an exciting
area of anti-cancer therapy [108]. Immunotherapy with mAbs targeting cytotoxic T lymphocytes
antigen 4 (CTLA-4), or the programmed cell death 1 (PD-1) and its ligand (PD-L1), have achieved
impressive success in the treatment of different types of cancer [109]. However, so far, clinical benefit
has been achieved in only a minority of patients across many cancer types [110]. Moreover, an immune
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checkpoint blockade poses a potentially high risk for developing severe immune-related adverse
effects [111–114]. Therefore, identification of truly predictive biomarkers is critical for personalizing
patient immunotherapy with immune checkpoint inhibitors (ICIs).
For example, PD-L1 expression on cancer cells as a biomarker for patient selection has been
approved for patients who are PD-L1 tumor cell positive [115]. However, multiple studies have not
detected a positive correlation between PD-L1 tumor expression and ICI response [109]. Increasing
evidence suggests that PD-L1 expression on immune cells (e.g., dendritic cells and macrophages)
in TME can determine the efficacy of PD-L1 pathway blockade-mediated tumor regression [116].
Mast cells express PD-L1 and, to a lesser extent, PD-L2 [117–119]. Intratumoral mast cells from gastric
cancer specimens express PD-1 [120]. Interestingly, PD-L1+ mast cells have been found in TME in the
early lung adenocarcinoma [119] and the number of PD-L1+ mast cells was equal to the density of
PD-L1+ macrophages. Further studies should evaluate systematically the percentage of PD-L1+ and
PD-L1− mast cells in the tumor core, tumor margin and in non-malignant distant tissue. The possibility
should be considered that the selection of patients for anti-PD-L1/PD-1 therapy could be based on
PD-L1+ expression on immune cells, including mast cells in TME.
4.4. Mast Cells in Tumor Draining Lymph Nodes
Mast cells are rarely found in normal lymph nodes [121,122], but the density of mast cells
is markedly increased in metastatic draining lymph nodes [38,123]. This suggests that mast cells
and/or their progenitors can migrate to tumor draining lymph nodes (TDLNs), where they might act
as non-professional antigen presenting cells (APCs) [121,124,125]. The mechanisms regulating the
trafficking of mast cells/mast cell progenitors into TDLNS, and their contributions to the evolving
microenvironment of the metastatic niche, remains poorly understood. High-dimensional analysis,
particularly single-cell RNA-seq, will be necessary to characterize the mast cell lineage in TDLNs.
4.5. Mast Cell Proteases in Cancer
Mast cell secretory granules contain various bioactive mediators, notably including several
proteases such as tryptase, chymase, and carboxypeptidase A3 (CPA3) [126]. The contribution of such
mast cell proteases to cancer is starting to be delineated. Pejler and collaborators elegantly demonstrated
that tryptase also can be found within the nucleus of mast cells and can truncate core histones [127,128].
More recently, the same group presented evidence that human recombinant tryptase can be taken
up into the nucleus of human melanoma cells causing truncation of histones [65]. Interestingly,
tryptase reduced melanoma cell growth in vitro by blocking proliferation [65]. Experimental studies in
genetically-altered mice indicate that the combined actions of chymase, tryptase and CPA3 protect
against the formation of lung metastasis of melanoma [129]. Thus, there was higher expression of
melanoma-specific genes in lungs of Mcpt4/Mcpt6/CPA3-deficient vs. wild type mice, and mice with
a Mcpt4/Mcpt6/Cpa3-deficiency also exhibited reduced numbers of cells expressing CD1d, an MHC
class 1-like molecule important for presenting antigen to invariant NKT (iNKT) cells. These findings
suggest that the protective role of mast cell-specific proteases in melanoma dissemination involves a
CXCL16/CD1d/NKT cell axis. Future studies should investigate, in additional tumor models, whether
mast cell proteases also can have protective roles in the formation of metastasis.
4.6. Influence of Microbiota on Mast Cells in Cancer
It is now clear that the microbiota can modulate the innate [130] and the adaptive immune
system [131]. Mast cells are located strategically at host-microbiota interfaces, including the skin and
the mucosae of the lung and of gastrointestinal tract. Mast cells have the ability to sense microorganism
or their metabolic products and to translate the signals into host pathophysiological responses [132].
Moreover, microbiota-derived metabolites signal to distant organs, which enables the host microbiota
to alter the immune system of the host [133].
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The microbiota is also involved in the initiation, progression and dissemination of cancer both
at epithelial barriers and in sterile tissues [134,135]. Recent evidence indicates that lung cancer
development is associated with local dysbiosis and chronic inflammation with neutrophil infiltration
and tumor cell proliferation [136]. Importantly, the intestinal microbiota has a major influence on the
effectiveness of anticancer immunosurveillance and thereby contributes to the therapeutic activity of
ICIs [137–140]. The skin microbiota can promote mast cell maturation by triggering SCF production
by keratinocytes [141]. Mast cells also can be activated by a variety of bacterial and viral products to
release a wide spectrum of proinflammatory and immunoregulatory mediators [66,142–144]. Further
studies will be needed to fully investigate the potentially diverse effects of the microbiota on mast cell
functions in tumorigenesis.
4.7. Adipose Tissue Mast Cells and Cancer
Up to 49% of certain types of cancer are now associated with obesity [145], and weight loss
can reverse cancer risk [146]. Obesity-associated inflammation can dramatically alter immune cell
composition in different tissues [147,148]. Indeed, there is evidence that obesity leads to metabolic
reprogramming of immune cells and limits anti-tumor responses [149]. White adipose tissue (WAT) from
humans and mice contains mature adipocytes and several immune cells including mast cells [150,151].
WAT also is a reservoir of functional mast cell progenitors [152–154]. Moreover, TNF-α of mast cells
from adipose tissue can induce apoptosis of cancer cells in vitro [56]. It therefore would be interesting
to evaluate whether obesity can influence mast cell responses during cancer initiation and progression.
4.8. C5a Receptor Signaling in Mast Cells and Cancer
Complement is a critical component of humoral immunity implicated in recognition and elimination
of pathogens and damaged cells, opsonization, and anaphylactoid reactions [155]. Complement is also
a critical component of humoral immunity involved in cancer development [156,157]. Human mast
cells express two C5a receptors (C5aR1 and C5aR2) [158] whose activation induces the release of
pro-inflammatory mediators [158–161]. C5aR1 signaling in mast cells and macrophages is thought
to foster carcinogenesis and C5aR1 inhibition improves response to chemotherapy [162]. Moreover,
blocking C5aR1 signaling promotes the anti-tumor efficacy of PD-1/PD-L1 blockade [163]. These results
provide evidence that C5a and signaling pathways downstream of the C5aR can regulate carcinogenesis
by promoting inflammation. Accordingly, the role of C5aR1-expressing mast cells as promoters of
cancer-associated inflammation merits further study.
4.9. IL-1, IL-33 and Mast Cells in Cancer
Inflammasome activation and IL-1β accelerate tumor invasiveness, growth, and metastatic
spread [78]. In IL-1β−/− mice, neither local tumors nor lung metastases develop after localized
or intravenous inoculations of melanoma cell lines, suggesting that this cytokine participates in
tumorigenesis in such models [79]. The Canakinumab Antiinflammatory Thrombosis Outcomes
Study (CANTOS) evaluated the efficacy of a human mAb targeting IL-1β in patients who had
myocardial infarction [164]. Additional data from the CANTOS trial suggested that inhibition of
IL-1β with increasing doses of canakinumab was associated with a dose-dependent reduction of
lung cancers [165]. In a prior study, the IL-1 receptor antagonist anakinra reduced the progression of
smoldering myeloma [166]. IL-1 can induce release of IL-6 from human mast cells [80] and of IL-8 [81]
contributing to angiogenesis [167]. Moreover, evidence from mice indicates that the mast cell-derived
IL-1β can mediate malignant pleural effusion [49]. Additional studies are needed to elucidate the role
of IL-1/mast cell interactions during cancer development, and to clarify whether the IL-1 blockade may
represent a valid approach in different types of cancer.
IL-33 is in the IL-1 family of cytokines that exerts pleiotropic activities [168]. In response to tissue
damage, infection or necrosis, IL-33 is released in the extracellular space where it functions as an
alarmin for the immune system [36]. IL-33 activates its receptor complex (ST2: IL-1RAcP) on a variety
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of immune cells including human mast cells [169] and basophils [170]. Moreover, IL-33 synergizes
with IgE- and non-IgE-dependent stimuli to release cytokines [171] and VEGF from human mast
cells [70]. It has been reported that IL-33 can upregulate the Fcγ receptor type IIa and can synergistically
enhance immune complex-triggered activation of human mast cells in vitro [172]. Single cell analysis
demonstrated that IL-33 could increase both the number of degranulating and chemokine-producing
mast cells and the magnitude of individual mast cell response [173].
Increasing evidence indicates that the IL-33/ST2 axis plays a role in tumor immunity [36]. However,
both pro-tumoral and anti-tumoral functions have been reported, and IL-33 may differently influence
tumor immunity depending on the tumor type, relevant immune cell targets, and microenvironmental
factors [174].
Mast cell activation by IL-33 [169,175] may occur in a variety of tumor types. In mouse skin
cancers, mast cells accumulated near IL-33-expressing fibroblasts in UV-exposed skin [176]. In the
ApcMin/+ mouse model, an IL-33 deficiency reduced tumor burden [177] and decreased mast cell
density in the colonic polyps, as well as suppressed the gene expression of mast cell proteases and
cytokines that promote angiogenesis, Treg function, and MDSC recruitment within the TME [178–180].
IL-33 also can exert anti-tumoral and anti-metastatic effects by conditioning other immune cells.
For example, IL-33 appears to inhibit B16 F10 melanoma through recruitment and activation of
eosinophils [181]. Although the role of IL-33 in tumorigenesis and cancer immunity thus remains
controversial, further studies should help to elucidate whether IL-33/ST2 signaling in mast cells can
contribute to human or experimental tumorigenesis.
4.10. Acidity, Hypoxia and Potassium as Modulators of Mast Cell Response and Tumor Progression
Typically, studies of immune cells are performed on cells isolated from peripheral blood or tissues,
where nutrients and O2 are generally abundant and pH is neutral. However, key features of the
TME are low pH and the accumulation of lactate (a byproduct of the anaerobic glycolytic pathway),
localized hypoxia [182,183] and elevated potassium [184,185]. These factors can alter the cellular
responses of tumor-associated immune cells including macrophages [186,187], T cells [184,185] and
mast cells [188]. For example, oxygen-glucose deprivation can induce mast cell degranulation and the
release of histamine [189] and of IL-6 [190] and lactic acid can inhibit IL-33- and lipopolysaccharide
(LPS)-mediated cytokine and chemokine production from mouse and human mast cells [188,191].
By contrast, another study reported that an acidic environment augments IgE-mediated production
of IL-6 and IL-13 from mouse mast cells [192]. Additional studies clearly are required to examine
the effects of lactic acid, hypoxia, and extracellular potassium on the release of proinflammatory and
angiogenic mediators from different types of mast cells activated by tumor-associated stimuli.
4.11. Canonical and Non-Canonical Angiogenic and Lymphangiogenic Factors from Mast Cells
Angiogenesis is a hallmark of cancer and is indispensable for fostering tumor growth [193].
In addition to tumors, several immune cells produce angiogenic factors within the TME [167]. Tumor
lymphangiogenesis occurs both in the primary tumors and/or in the formation of metastasis [84,194].
VEGF-A is the most potent canonical pro-angiogenic molecules, while VEGF-C and -D are the canonical
lymphangiogenic factors [195,196]. Mast cells represent a potential source of VEGF-A [45,70–74] and
only tissue resident immune cells such as macrophages [197] and mast cells, are thought to produce
lymphangiogenic factors [45]. Mast cells also express two isoforms of VEGF-B [45] which can play
roles in tumorigenesis [100]. Mast cells also can exert a pro-tumorigenic role through the production of
CXCL8 [48] and MMP-9 [75].
There is also evidence that cysteinyl leukotrienes (cys-LTs), major lipid mediators of mast
cells, can promote tumor angiogenesis via the activation of the cys-LT receptor, CysLT2R [198–200].
Interestingly, a CysLT2R antagonist reduced tumor growth in mice, suggesting that this receptor could
be a possible target in the modulation of tumorigenesis [200].
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Although lymphangiogenesis has been canonically associated with the formation of metastasis,
there is increasing evidence that the lymphatic system also can contribute to the resolution
of inflammation [67,68]. In addition, there is evidence that lymphatic vessels can exert an
immunomodulatory role and participate in immune surveillance [68]. More investigation is necessary
to verify the possibility that the production of lymphangiogenic factors from tumor-associated mast
cells can contribute not only to the formation of metastasis, but, in certain conditions, to the resolution
of tumor-associated inflammation.
5. Mast Cells in Cardiovascular Diseases
Recently, there has been increased interest in the potential involvement of mast cells in
cardiometabolic disorders [201–203]. In the human myocardium, mast cells are located in close
proximity to cardiomyocytes, coronary microvessels, nerves, and lymphatic vessels [159,204–207].
Figure 2 illustrates some of the mediators produced or acting on cardiac mast cells. Unsurprisingly,
mast cells and their powerful vasoactive and proinflammatory mediators (e.g., histamine, tryptase,
chymase, prostaglandin D2 (PGD2) and cysteinyl leukotriene C4 (LTC4)) were considered to be net
detrimental in atherosclerosis [151,207–210], myocardial infarction [211,212], myocarditis [213–215],
dilated cardiomyopaties [159,201], hypertension [216,217] and thrombosis [218].
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participating in the homeostatic control of the cardiac renin-angiotensin system (RAS) [224,225].
Immunologically-activated human cardiac mast cells release angiogenic (VEGF-A and VEGF-B) and
lymphangiogenic factors (VEGF-C) [66,226,227], which can act on blood endothelial cells (BECs) and
lymphatic endothelial cells (LECs), respectively. Matrix metalloproteinases (MMPs) released from mast
cells can contribute to extracellular matrix remodeling leading to cardiac fibrosis [228]. Tryptase, TGF-β,
and histamine activate fibroblasts to produce collagen [228,229]. Fibroblasts also produce stem cell
factor (SCF), the main growth and differentiating factor for mast cells that acts via the engagement of
the KIT receptor [8]. Human myocardial mast cells contain and release SCF, which might represent an
autocrine factor sustaining mast cell hyperplasia in cardiac disorders [204]. Eosinophils and eosinophil
granule proteins (i.e., eosinophil cationic protein (ECP) and major basic protein (MBP)) have been
detected in endomyocardial biopsies from patients with hypereosinophilia [230,231]. ECP and MBP can
induce the release of proinflammatory mediators from human cardiac mast cells [159]. Human cardiac
mast cells interact with macrophages through the release of histamine and IL-6 (Marone, unpublished
results). Mast cell tryptase modulates cardiomyocyte contractility through the engagement of the
PAR-2 receptor [219]. Histamine, tryptase, TNF-α, and IL-1β can modulate several functions of
cardiomyocytes [219,232]. Finally, heterogeneous and ontogenetically diverse macrophages reside in
the healthy heart, and accumulate in increased numbers in diseased hearts [233].
However, recent studies have revealed that cardiac mast cells may participate both in physiological
and pathological processes in the heart. There is evidence that mast cells can participate in the formation
of new blood vessels (angiogenesis) as well as lymphatic vessels (lymphangiogenesis), which are vital
processes during the embryologic development of the heart and during myocardial wound healing
after myocardial infarction [234,235]. Moreover, immunologic and superantigenic stimuli can induce
the release of proangiogenic (VEGF-A) and lymphangiogenic (VEGF-C) factors from primary human
cardiac mast cells [66,226]. Notably, the production of VEGF-C by human cardiac mast cells can exert a
potentially cardioprotective effect, since activation of the cardiac lymphatics improves the resolution
of inflammation [67,236] and has an essential role in counteracting myocardial edema [68,237,238].
Interestingly, the activation of the protease activated receptor 2 (PAR-2) on cardiomyocytes by tryptase
following experimental myocardial infarction also can exert a net protective effect [219].
Moreover, cardiac mast cells are located near neuropeptide substance P-positive sensory nerves
both in the myocardium and in the adventitial layers of the coronary arteries [206,239]. Substance
P, released by sensory nerves, can activate adventitial mast cells [206], presumably, through the
engagement of MAS-related G protein-coupled receptor-X2 (MRGPRX2) receptor to release several
proinflammatory mediators. In the mouse, a similar system has also been identified as an underlying
mechanism that promotes the development of type 2 skin inflammation in response to certain allergens,
including house dust mites and Staphylococcus aureus [240].
Mast cells also can induce a protective response against microbial pathogens and other
noxious substances by releasing soluble mediators (e.g., TNF-α, proteases) [126,241,242]. Indeed,
MRGPR-mediated activation of local mast cells has been shown to help clear cutaneous bacterial
infection and to protect against reinfection in mice [243]. In humans with chronic rhinosinusitis with
nasal polyps, mast cells may help in defense against Staphylococcus aureus (S. aureus), particularly in the
presence of S. aureus enterotoxin B (SEB), by ejecting extracellular DNA traps (Mast Cell Extracellular
Traps: MCETs) [244]. MCETs can also be generated during coronary atherothrombosis in patients who
died from myocardial infarction [245]. However, since activated mast cell-formed MCTEs are involved
in the elimination of pathogens [246,247], cardiac mast cells also might contribute to the resolution of
infectious myocarditis. Additional knowledge regarding the role of MCETs during cardiovascular
diseases may provide new strategies for the treatment of these disorders.
In patients with cardiomyopathies, mast cell density in the myocardium is markedly increased [204].
Moreover, the release of preformed and de novo synthesized mediators from cardiac mast cells derived
from these patients was increased when compared to results from mast cells of control subjects without
cardiovascular disease [204]. Mast cells contain and release several cytotoxic mediators such as
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TNF-α [56–59,248] and granzyme B [60,61]. Given the proximity of mast cells to cardiomyocytes and
the ability of mast cells to release cytotoxic mediators, there is a possibility that mast cells can contribute
to myocardial damage by this mechanism.
However, it is likely that different subsets of mast cells, like those of cardiac macrophages [249–252],
can exert distinct, and even opposite, effects in different pathophysiological process in the heart.
Recent fate mapping experiments demonstrate that mast cells form a highly heterogeneous
population of immune cells [3,4], similar to T cells [101,103] and macrophages [94,102]. We speculate
that single-cell analyses of different sections of heart will likely identify subsets of myocardial mast
cells, and will help to elucidate their functions in different pathophysiological conditions. Indeed,
mast cells likely comprise distinct subsets of cells, like subpopulations of resident cardiac macrophages
that can promote both injury and repair after myocardial infarction [253].
Accordingly, we think that two questions need to be addressed. Can mast cell precursors, like for
T cells [101,103] and macrophages [249–252], generate functionally distinct subsets of cardiac mast
cells with beneficial or harmful activities? Alternatively, do individual differentiated cardiac mast
cells have enough plasticity to develop distinct, sometimes opposite, characteristics in response to
local and/or systemic environmental stimuli (Figure 2)? Whatever the answer to these questions,
the characterization of subpopulations of cardiac mast cells by single-cell RNA-seq, together with
analysis of the encoded proteins, may be of importance in efforts to modulate pharmacologically or
genetically the injury- or repair-inducing abilities of these cells.
6. Outstanding Questions and Conclusions
We have briefly reviewed some of the many potential roles of mast cells in health and disease,
with a particular focus on tumor biology and cardiovascular disorders. However, we hope that we also
have illustrated how difficult it can be to prove that mast cells have particular roles in vivo. Inbred
mice are quite useful for this purpose, in that there now are multiple strains with profound constitutive
or inducible mast cell deficiencies—but none of these produce mice that are solely and completely
devoid of all mast cells. For example, in some cases, the genetic effects influence basophil numbers and
functions, as well as numbers of mast cells [254] and in other cases particular subtypes of mast cells are
deleted, without influencing other mast cell populations [255]. In addition, the ablation of mast cells,
while in some cases profound, is rarely 100%. Finally, “mast cell-deficient” mice have been derived
primarily on the C57BL/6 background and, to a lesser extent, on BALB/c. Accordingly, work with such
animals produces results that might be mainly restricted to those strains of inbred mice. The relevance
of the findings to the roles of mast cells in other strains of mice, and, more importantly, to humans,
remains to be established.
Finally, to our knowledge, no drug has yet been reported that solely and selectively targets mast
cells. Therefore, while we have reviewed much work suggesting that mast cells may have significant
effects on diverse biological responses in mice or in humans, proof of such roles, especially in humans,
remains elusive.
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